[Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells].
Treated with low dosage (5 ng.ml-1) of staurosporine for 18 h, human embryo lung 2BS cells were blocked at the G1/S boundary, but human gastric carcinoma BGC-823 cells still kept their cell cycle. In comparison with IC50 of 2BS and BGC-823 cells treated with cell cycle phase specific antitumor drugs adriamycin, Ara-C and BLM A5 alone or combined with staurosporine 5 ng.ml-1, the IC50 values increased from 0.325 microgram.ml-1, 5 micrograms.ml-1 and 6.5 micrograms.ml-1 to 0.45 microgram.ml-1, 10 micrograms.ml-1 and 6.5 micrograms.ml-1, respectively in 2BS cells; but decreased from 0.325 microgram.ml-1, 25 micrograms.ml-1 and 1.1 micrograms.ml-1 to 0.07 microgram.ml-1, 6.25 micrograms.ml-1 and 0.4 microgram.ml-1, respectively in BGC-823 cells. These results suggest that combination of staurosporine 5 ng.ml-1 with antitumor drugs showed different effects on tumor cells and normal cells. With the GSH fluorescent probe mBCL, we found that GSH contents increased in 2BS cells treated with staurosporine 5 ng.ml-1.